Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults
Public ClinicalTrials.gov record NCT05975840. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I/II Observer-blind, Randomized, Multi-center Trial to Evaluate the Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System (Referred to as Q-Pan H5N8), Given as a Two-dose Series to Adults 18 to 64 Years of Age and 65 Years of Age and Older
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the safety and immunogenicity of different formulations of monovalent Influenza A/Astrakhan/3212/2020-like virus vaccine with AS03 adjuvant system in adults greater than or equal to (\>=)18 years of age.
Study identification
- NCT ID
- NCT05975840
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 518 participants
Conditions and interventions
Conditions
Interventions
- FLU Q-PAN H5N8 375_B Biological
- FLU Q-PAN H5N8 375_A Biological
- FLU Q-PAN H5N8 750_B Biological
- FLU Q-PAN H5N8 750_A Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 3, 2023 (Actual)
- Primary completion
- May 21, 2024 (Actual)
- Completion
- Sep 19, 2024 (Actual)
- Last update posted
- Aug 19, 2025
2023 – 2024
United States locations
- U.S. sites
- 20
- U.S. states
- 13
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Anniston | Alabama | 36207 | — |
| GSK Investigational Site | Mobile | Alabama | 36608 | — |
| GSK Investigational Site | Tempe | Arizona | 85281 | — |
| GSK Investigational Site | Chula Vista | California | 91911 | — |
| GSK Investigational Site | Long Beach | California | 90806 | — |
| GSK Investigational Site | Santa Ana | California | 92705 | — |
| GSK Investigational Site | Pembroke Pines | Florida | 33025 | — |
| GSK Investigational Site | Chamblee | Georgia | 30341 | — |
| GSK Investigational Site | Meridian | Idaho | 83642 | — |
| GSK Investigational Site | El Dorado | Kansas | 67042 | — |
| GSK Investigational Site | Lenexa | Kansas | 66219 | — |
| GSK Investigational Site | Lexington | Kentucky | 40509 | — |
| GSK Investigational Site | Metairie | Louisiana | 70006 | — |
| GSK Investigational Site | Anderson | South Carolina | 29621 | — |
| GSK Investigational Site | Knoxville | Tennessee | 37920 | — |
| GSK Investigational Site | Austin | Texas | 78745 | — |
| GSK Investigational Site | Boerne | Texas | 78006 | — |
| GSK Investigational Site | San Antonio | Texas | 78244 | — |
| GSK Investigational Site | Tomball | Texas | 77375 | — |
| GSK Investigational Site | Norfolk | Virginia | 23507 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05975840, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 19, 2025 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05975840 live on ClinicalTrials.gov.